Arvinas (NASDAQ:ARVN) Sets New 1-Year Low – What’s Next?

Arvinas, Inc. (NASDAQ:ARVN) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $16.43 and last traded at $16.26, with a volume of 210125 shares. The stock had previously closed at $17.77.

Analysts Set New Price Targets

ARVN has been the topic of several research reports. BTIG Research initiated coverage on shares of Arvinas in a research report on Tuesday, December 10th. They issued a “buy” rating and a $69.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and set a $57.00 target price on shares of Arvinas in a report on Tuesday, February 11th. Barclays lowered their price objective on Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $82.00 target price (down from $88.00) on shares of Arvinas in a research note on Wednesday, February 12th. Finally, Guggenheim reiterated a “buy” rating and issued a $57.00 price objective on shares of Arvinas in a report on Wednesday, February 12th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Arvinas has an average rating of “Buy” and an average price target of $60.00.

Arvinas Stock Performance

The stock has a market cap of $1.21 billion, a P/E ratio of -6.38 and a beta of 1.88. The company’s fifty day moving average price is $18.41 and its 200-day moving average price is $22.80.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the previous year, the firm posted ($2.53) earnings per share. Analysts anticipate that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO John G. Houston sold 31,338 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the sale, the chief executive officer now directly owns 1,157,480 shares of the company’s stock, valued at $19,353,065.60. This represents a 2.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Ian Taylor sold 9,020 shares of Arvinas stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the sale, the insider now directly owns 159,121 shares in the company, valued at $2,658,911.91. This represents a 5.36 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 41,572 shares of company stock valued at $695,030. Company insiders own 5.23% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its position in shares of Arvinas by 18.7% during the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock worth $57,371,000 after acquiring an additional 367,343 shares during the period. Baker BROS. Advisors LP acquired a new stake in shares of Arvinas in the third quarter valued at approximately $9,989,000. SG Americas Securities LLC grew its position in Arvinas by 228.8% during the 4th quarter. SG Americas Securities LLC now owns 32,424 shares of the company’s stock worth $622,000 after purchasing an additional 22,564 shares during the last quarter. Wasatch Advisors LP increased its position in Arvinas by 58.3% in the 3rd quarter. Wasatch Advisors LP now owns 435,943 shares of the company’s stock valued at $10,737,000 after acquiring an additional 160,510 shares during the period. Finally, Barclays PLC increased its holdings in shares of Arvinas by 198.9% in the third quarter. Barclays PLC now owns 121,699 shares of the company’s stock valued at $2,998,000 after purchasing an additional 80,984 shares during the period. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.